

Welcome	3
Organisation	4
Programma overview	6
Scientific Programme	10
Who should attend	30
Accreditation	30
Registration	31
Social Programme	32
Venue	32
Language	32
Hotel Accommodation	32
Flights and Public Transportation	32
Visa Procedure	33
Important Dates and Addresses	34

**NIEUW**  
Diovan 320mg

# De **voorsprong** met Diovan en Co-Diovan

## effectiviteit Diovan

**21**

mmHg

tot 21 mmHg systolische  
80-daling met  
Diovan 160 mg<sup>1</sup>

**3**

indicaties

3 indicaties met Diovan<sup>2</sup>  
(geldt voor 80 en 160 mg)

**1**

Wereldwijd

Diovan: wereldwijd de  
meest voorgeschreven AIIA<sup>3</sup>

## effectiviteit Co-Diovan

**30**

mmHg

tot 30 mmHg systolische  
80-daling met  
Co-Diovan 160/25 mg<sup>2</sup>

**3**


doseringen

met Co-Diovan<sup>4</sup>

**1**

Wereldwijd

Co-Diovan: wereldwijd de  
meest voorgeschreven AIIA<sup>3</sup>

 NOVARTIS

De startdosering voor de behandeling van hypertensie met Diovan is 80 mg. Het advies is de behandeling met Co-Diovan 160/25 mg vooraf te laten gaan door 4-8 weken Co-Diovan 160/12,5 mg. Aanbevolen startdosering Diovan is 80 mg. Titratieschema Diovan: van 80 mg oplopen naar 160 mg en van 160 mg naar 320 mg.

 **Co-Diovan**<sup>®</sup>  **DIOVAN**<sup>®</sup>

0470202387

Dear colleagues and friends,

We would like to welcome you all to the 8th conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT) in Amsterdam. The Dutch Society for Clinical Pharmacology and Biopharmacy, which was established in 1979 and today has over 300 active members, is greatly honoured to be hosting this meeting. It has been actively involved in EACPT programmes and activities since the latter was founded.

The profession of clinical pharmacology is becoming increasingly important today. Our European health care maintains high standards of general medicine, and the EACPT provides professional and educational information on clinical pharmacology and pharmacotherapy. In addition, the EACPT is involved in comprehensive research and training programmes in all member states of our Association.

Furthermore, clinical pharmacologists provide professional services to the pharmaceutical industry to enable the swift development of new drugs that benefit patients, and many of them are employed by this industry. They also provide professional services to other important organisations, such as drug regulatory authorities. All these important aspects of clinical pharmacology and pharmacotherapy and many new developments, especially those related to the conference theme of "patient-tailored pharmacotherapy", will be presented at this EACPT conference in Amsterdam.

The EACPT conference will be held in the RAI Convention Centre in Amsterdam. The RAI is the ideal venue for this conference because of its state-of-the-art conferencing facilities, its central location close to Schiphol international airport, competitive hotel accommodation in the vicinity of the conference centre and the excellent sightseeing opportunities and cultural offerings of our capital city. We wish you a very fruitful conference and hope you will enjoy the many different sessions of the meeting as well as the hospitality and cultural highlights of the city of Amsterdam.

With best regards on behalf of the organising committee,  
Professor Jan HM Schellens

### Chairperson:

J.H.M. Schellens, the Netherlands Cancer Institute

### Organizing Scientific Committee:

A. de Boer, Utrecht University  
J.H. Beijnen, Slotervaart Hospital-the Netherlands Cancer Institute  
L.M. Van Bortel, Ghent University  
A.R.J. Girbes, VU Medical Center Amsterdam  
P.A. de Graeff, University Medical Center Groningen  
R.J.E. Grouls, Catharina Hospital  
E.J. van Hoogdalem, OctoPlus  
P.A. van Meurs, Allevon Research Institute  
R.W. van Olden, Eli Lilly Nederland  
G. Rongen, Radboud University Medical Center Nijmegen  
P. Smits, Radboud University Medical Center Nijmegen

### International Scientific Committee:

N. Boada (ES)	N. Moore (FR)
K. Brösen (DK)	P.M. Mrozikiewicz (PL)
I. Cascorbi (DE)	M. Orme (UK)
J. Cockroft (UK)	A. Rane (SW)
K. Dalhoff (DK)	A. Sabo (YU)
J. Desmeules (CH)	P.A. Thürmann (DE)
I. Francetic (CR)	C. Tulunay (TU)
P. Geppetti (IT)	A. Vas (HU)
J. Gulbinovic (LT)	G.P. Velo (IT)
J. Martinkova (CZ)	D.J. Webb (UK)

### Local Organising Committee:

J.R.M. van Dulmen Congress & Meeting Services Holland  
E.M.C. Triebels, Dutch Society for Clinical Pharmacology & Biopharmacy

### Conference Secretariat:

Congress & Meeting Services Holland  
P.O. Box 18  
5298 ZG LIEMPDE  
The Netherlands  
T +31 (0)411 611199  
F +31 (0)411 633805  
eacpt@congressservice.nl  
www.eacpt2007.nl

## European Association for Clinical Pharmacology and Therapeutics cooperates with:

ARTERY: Association for Research into Arterial Structure and Physiology

ENOTT: European Network of Therapeutic Teachers

EURO-DURG: European Drug Utilisation Research Group

IFAPP: International Federation of Associations of Pharmaceutical Physicians

ISOP: International Society of Pharmacovigilance

ISPE: The International Society for Pharmacoepidemiology

ISPOR: International Society for Pharmacoeconomics and Outcomes Research

IUPHAR: International Union of Basic and Clinical Pharmacology

## EACPT wishes to acknowledge the generosity of the following sponsors:

### Major Sponsor:



### Sponsors & Exhibitors:

ABL

Bristol-Myers Squibb

Centre for Human Drug Research

ClinPharmCologne

Eisai

Eli Lilly Nederland

Kendle International

National Advanced Driving Simulator, The University of Iowa

Novartis Pharma

Novo Nordisk Farma

Organon

Pharmaceutical Profiles

PRA International

Promasys

Sanofi Aventis

SGS Life Sciences

Shimadzu Benelux

TI Pharma

Wiley Blackwell

Wolters Kluwer

Xceleron

Xendo Drug Development

## Tuesday 28 August

14.00 - 20.00	Registration desk open at the RAI	Entrance RAI
15.00 - 17.00	Premeetings presentation training	Room C
15.00 - 18.00	Satellite Centre for Human Drug Research	Muziekgebouw aan 't IJ
19.00 - 20.00	Informal opening ceremony	City Hall of Amsterdam

## Wednesday 29 August

08.30 - 09.00	Official Opening Ceremony	Auditorium 1
09.00 - 09.30	Conference Theme	• Patient tailored pharmacotherapy Auditorium 1
09.30 - 10.00	Sessions	• Rheumatology • Teaching <b>in collaboration with ENOTT</b> • Cardiovascular <b>in collaboration with ARTERY</b> Auditorium 1 Room A Room B
10.00 - 10.30	Coffee break	
10.30 - 11.30	Sessions	• Rheumatology • Pro-Con + Late breaking abstract • Cardiovascular <b>in collaboration with ARTERY</b> Auditorium 1 Room A Room B
11.30 - 12.15	Plenary session	Auditorium 1
12.15 - 13.00	Lunch and poster viewing	Poster area
13.00 - 14.00	Guided poster viewing	Poster area
14.00 - 14.30	Plenary poster discussion + Best poster award	Auditorium 1
14.30 - 15.45	Sessions	• Drug discovery oncology • Teaching <b>in collaboration with ENOTT</b> • Analgesics Auditorium 1 Room A Room B
15.45 - 16.15	Coffee break	
16.15 - 17.00	Pharmaco-therapeutic cases	• Drug discovery oncology • Teaching <b>in collaboration with ENOTT</b> • Analgesics Auditorium 1 Room A Room B
17.00 - 18.45	Satellite Novartis	Room A
17.00 - 18.45	Satellite Sanofi Aventis	Room B

## Thursday 30 August

07.30 - 08.30	Meet the expert sunrise sessions		Auditorium 1
		<ul style="list-style-type: none"> <li>• Drug regulation</li> <li>• Cardiovascular</li> <li>• Neuropsychopharmacology</li> </ul>	Room A Room B
08.30 - 10.00	Sessions	<ul style="list-style-type: none"> <li>• Drug regulation</li> <li>• Cardiovascular</li> <li>• Neuropsychopharmacology</li> </ul>	Auditorium 1 Room A Room B
10.00 - 10.30	Coffee break		
10.30 - 11.30	Sessions	<ul style="list-style-type: none"> <li>• Drug regulation</li> <li>• Pro-Con + Late breaking abstract</li> <li>• Neuropsychopharmacology</li> </ul>	Auditorium 1 Room A Room B
11.30 - 12.15	Plenary session		Auditorium 1
12.15 - 13.00	Lunch and poster viewing		Poster area
13.00 - 14.00	Guided poster viewing		Poster area
13.00 - 14.00	General Assembly		Auditorium 1
14.00 - 14.30	Plenary poster discussion + Best poster award		Auditorium 1
14.30 - 15.45	Sessions	<ul style="list-style-type: none"> <li>• Clinical research in EU under the EU Directive <i>in collaboration with IFAPP</i></li> <li>• Pharmacovigilance <i>in collaboration with ISOP</i></li> <li>• Oncology</li> </ul>	Auditorium 1 Room A Room B
15.45 - 16.15	Coffee break		
16.15 - 17.00	Pharmacotherapeutic cases	<ul style="list-style-type: none"> <li>• Clinical research in EU under the EU Directive <i>in collaboration with IFAPP</i></li> <li>• Pharmacovigilance <i>in collaboration with ISOP</i></li> <li>• Oncology</li> </ul>	Auditorium 1 Room A Room B
14.00 - 17.00	Symposium TI Pharma/Figon		Room C
17.00 - 18.00	Council Meeting (nominated delegates only)		Room C
17.00 - 18.45	Satellite IFAPP		Auditorium 1
	Satellite GlaxoSmithKline		Room A
	Satellite Xceleron		Room B
18.45 - 19.30	 Happy Hour		

## Friday 31 August

07.30 - 08.30	Meet the expert sunrise session • Pharmacoeconomics <i>in collaboration with ISPE</i> • Critical care medicine • Metabolic disorders	Auditorium 1 Room A Room B
08.30 - 10.00	Sessions • Pharmacoeconomics <i>in collaboration with ISPE</i> • Critical care medicine • Metabolic disorders	Auditorium 1 Room A Room B
10.00 - 10.30	Coffee break	
10.30 - 11.30	Sessions • Pharmacoeconomics <i>in collaboration with ISPE</i> • Pro-Con + Late breaking abstract • Pediatric pharmacotherapy	Auditorium 1 Room A Room B
11.30 - 12.15	Plenary session	Auditorium 1
12.15 - 13.00	Lunch and poster viewing	Poster area
13.00 - 14.00	Guided poster viewing	Poster area
14.00 - 14.30	Plenary poster discussion + Best poster award	Auditorium 1
14.30 - 15.45	Sessions • Pharmacoeconomics <i>in collaboration with ISPOR</i> • Digestive tract • Pulmonology	Auditorium 1 Room A Room B
15.45 - 16.15	Coffee break	
16.15 - 17.00	Pharmaco-economics cases • Pharmacoeconomics <i>in collaboration with ISPOR</i> • Digestive tract • Pulmonology	Auditorium 1 Room A Room B
19.30 - 24.00	Conference dinner	NH Grand Hotel Krasnapolsky

## Saturday 1 September

07.30 - 08.30	Meet the expert sunrise session <ul style="list-style-type: none"> <li>• Rational prescribing in collaboration with EURO-DURG</li> <li>• Pharmacokinetics</li> <li>• Geriatric clinical pharmacology</li> </ul>	Auditorium 1  Room A Room B
08.30 - 10.00	Sessions <ul style="list-style-type: none"> <li>• Rational prescribing in collaboration with EURO-DURG</li> <li>• Pharmacokinetics</li> <li>• Geriatric clinical pharmacology</li> <li>• Antimicrobial use – European concerns in collaboration with IUPHAR</li> </ul>	Auditorium 1  Room A Room B Room C
10.00 - 10.30	Coffee break	
10.30 - 11.30	Sessions <ul style="list-style-type: none"> <li>• Rational prescribing and pharmacogenetics</li> <li>• Workshop on population analysis</li> <li>• Pro-con + Late breaking abstract</li> <li>• Antimicrobial use – European concerns in collaboration with IUPHAR</li> </ul>	Auditorium 1  Room A Room B Room C
11.45 - 12.30	Closing ceremony	Auditorium 1
12.30 - 14.00	Lunch	Poster Area

Scientific content of the Satellite programmes is not covered by the Organising Scientific Committee of EACPT2007.

Tuesday 28 August 2007

14.00 - 20.00 Registration desk open at the RAI

**Room C**

15.00 - 17.00

**Premeetings:**

Presentation training on selected abstracts (also open to all attendees to EACPT2007)

*Chairpersons:*

A. de Boer (NL)

P.A. de Graeff (NL),

P.A. Thürmann (DE)

Speakers will have the opportunity to present their paper and will obtain advice for optimal presentation during the EACPT meeting.

19.00 - 20.00

Informal welcome at City Hall of Amsterdam

Wednesday 29 August 2007

**Auditorium 1**

**Official Opening Ceremony**

08.30 - 08.40

J.H.M. Schellens (NL)

08.40 - 08.50

M. Orme (UK)

08.50 - 09.00

D. Crommelin (NL)

**Auditorium 1**

**Conference Theme:**

Patient tailored pharmacotherapy

09.00 - 09.30

Speaker I 1

M. Bogaert (BE)

**Auditorium 1**

**Rheumatology**

*Chairpersons:*

P. Emery (UK)

P.L.C.M. van Riel (NL)

09.30 - 10.00

Invited lecture

Title:

The use of COX-inhibitors in arthritis revisited

Speaker I 2

P.L.C.M. van Riel (NL)

10.00 - 10.30

Coffee

10.30 - 10.45

Abstract O 01

The influence of cyclosporin on the treatment of blood pressure and some biomarkers in patients with rheumatic diseases

M. Grundmann (CZ)

10.45 - 11.00      Abstract 0 02      Treatment of pregnant and non-pregnant patients. A survey among Dutch rheumatologists  
F. Vroom (NL)

11.00 - 11.30      Invited lecture  
Title:      Treatment with monoclonal antibodies in rheumatoid arthritis. When and What?  
Speaker I 3      P. Emery (UK)

**Room A**

**Teaching**

*Chairpersons:*  
S. Kerpel-Fronius (HU)  
K. Franson (NL)

**In collaboration with ENOTT**

09.30 - 10.00      Teaching  
Title:      E-learning as a new method or material for measuring success in teaching clinical pharmacology  
Speaker I 4      B. Chamontin (FR)

10.00 - 10.30      Coffee

**Room A**

**Pro-con**

*Chairpersons:*  
D. Webb (UK)  
P. Smits (NL)

10.30 - 10.45      Title:      Pro: "Mechanism-based medicine" as the basis for pharmacotherapy  
Speaker I 5      J. Cockcroft (UK)

10.45 - 11.00      Title:      Con: "Evidence-based medicine" as the basis for pharmacotherapy  
Speaker I 6      F. Zannad (FR)

11.00 - 11.10      Plenary Discussion

11.10 - 11.30      Late breaking presentation  
Abstract 0 03      Interactions between the Gly460Trp alpha-adducin gene variant and diuretics and the risk of myocardial infarction among treated hypertensive patients  
B.M.A. van Wieren - de Wije (NL)

**Room B**

**Cardiovascular**

*Chairpersons:*  
L.M. Van Bortel (BE)  
M.J.F. Starmans-Kool (NL)

**In collaboration with ARTERY**

09.30 - 09.45	Abstract O 04	Discontinuation of beta-blockers and risk of myocardial infarction in elderly M. Teichert (NL)
09.45 - 10.00	Abstract O 05	Endothelial function in migraine F.H.M. Vanmolkot (BE)
10.00 - 10.30	Coffee	
10.30 - 10.45	Abstract O 06	Does the angiotensin-AT1 receptor antagonist irbesartan reduce ischemia reperfusion injury in humans in-vivo? C. Wouters (NL)
10.45 - 11.00	Abstract O 07	Hypotensive therapy and vascular flow in the central retinal artery A.M. Madej (PL)
11.00 - 11.30	Invited lecture Title: Speaker I 7	Pharmacotherapeutic opportunities in the management of arterial stiffness L.M. Van Bortel (BE)
<b>Auditorium 1</b>	<b>Plenary session</b> <i>Chairpersons:</i> K. Brösen (DK) J.H.M. Schellens (NL)	
11.30 - 12.15	Invited lecture Title: Speaker I 8	Bias in design and interpretation of clinical trials P.C. Gotzsche (DK)
<b>Poster area</b>		
12.15 - 13.00	Lunch + Poster viewing	
13.00 - 14.00	Guided Poster viewing	
<b>Auditorium 1</b>		
14.00 - 14.30	Plenary Poster discussion + Best Poster Award Moderator:	D.J. Webb (UK)
<b>Auditorium 1</b>	<b>Drug discovery and Development Oncology</b> <i>Chairpersons:</i> D.R. Newell (UK) J.H. Beijnen (NL)	
14.30 - 14.45	Abstract O 08	New development and bioanalytical studies of the bioreductive agent E09 L.D. Vainchtein (NL)

14.45 - 15.00	Abstract O 09	Mentha piperita Linn: Radio-protective and chemopreventive studies in Swiss albino mice M. Samartha (IND)
15.00 - 15.15	Abstract O 10	Irinotecan metronomic chemotherapy clinical trial in metastatic colorectal cancer G. Pasqualetti (IT)
15.15 - 15.45	Invited lecture Title: Speaker I 9	Drug discovery in oncology: focus on cell cycle inhibitors D.R. Newell (UK)
15.45 - 16.15	Coffee	
16.15 - 17.00	Pharmacotherapeutic case Subject: Title: Speaker I 10	Oncology <a href="#">Conference Theme Event</a> Practice and pitfalls in therapeutic drug monitoring of anticancer drugs H.P. Lipp (DE)
<b>Room A</b>	<b>Teaching</b> <i>Chairpersons:</i> M. Orme (UK) P.A. de Graeff (NL)	<b>In collaboration with ENOTT</b>
14.30 - 14.45	Abstract O 11	Effect of a preclinical pharmacotherapy context-learning programme on rational prescribing of medical students during the clinical clerkship internal medicine M.C. Richir (NL)
14.45 - 15.00	Abstract O 12	The short term impact of rational pharmacotherapy education in the fifth year medical students in Gazi University Medical School, Ankara, Turkey Z. Guney (TU)
15.00 - 15.15	Abstract O 13	The 6-Step: Validation of the Dutch national standard for a therapeutic plan K.L. Franson (NL)
15.15 - 15.45	Invited lecture Title: Speaker I 11	Achieving competency in pharmacotherapy – are European medical students adequately prepared? S. Maxwell (UK)
15.45 - 16.15	Coffee	

- 16.15 - 16.30      Abstract O 14      Initial experiences of inter-professional learning - a viable means of enhancing undergraduate clinical pharmacology and therapeutics  
J. Quinn (UK)
- 16.30 - 17.00      Pharmacotherapeutic case  
Subject:            Teaching  
Title:                Evidence based assessment of pharmacotherapy teaching  
Speaker I 12        Th.P.G.M. de Vries (NL)
- 17.00 - 18.45      **Satellite symposium Novartis Pharma**  
Direct Renin Inhibition: the next step in RAS inhibition  
17.00 - 17.45      Professor Juerg Nussberger, Lausanne (Switzerland)  
17.45 - 18.30      Professor Jan Danser, University Hospital of Rotterdam (the Netherlands)

**Room B**

**Analgesics**

*Chairpersons:*

C. Tulunay (TU)  
R.J.E. Grouls (NL)

- 14.30 - 14.45      Abstract O 15      MK-0974, an oral CGRP antagonist, inhibits capsaicin-induced vasodilation in the human skin  
J. Van der Schueren (BE)
- 14.45 - 15.15      Invited lecture  
Title:                Novel approaches in the treatment of neuropathic pain  
Speaker I 13        J. Desmeules (CH)
- 15.15 - 15.45      Invited lecture      [Conference Theme Event](#)  
Title:                Opioid rotation  
Speaker I 14        J. Devulder (BE)
- 15.45 - 16.15      [Coffee](#)
- 16.15 - 17.00      Pharmacotherapeutic case  
Subject:            Pain  
Title:                A patient with headache  
Speaker I 15        C. Tulunay (TU)
- 17.00 - 18.45      **Satellite symposium Sanofi aventis**  
Farmacological and Therapeutical Aspects of The Endocannabinoid System and it's Inhibition via Selective CB1-receptor Blockade  
Prof. Dr. U. Pagotto, Orsola Malpighi Hospital, Bologna  
Prof. Dr. L. Van Gaal, UZA, Antwerp

## Thursday 30 August 2007

**Auditorium 1**

07.30 - 08.30

**Meet the expert sunrise session**

Title: Developments in drug registration in Europe  
 Speaker I 16 B.J. van Zwieten-Boot (NL)

**Auditorium 1**

08.30 - 08.45

**Drug Regulation***Chairpersons:*

J. Desmeules (CH)

P.A. de Graeff (NL)

Abstract O 16

Current Assessment of Risk-Benefit by Regulators:  
 Is it time to introduce decision analyses?

A. Hughes (UK)

08.45 - 09.00

Abstract O 17

The safety of healthy volunteers in First in Man trials -  
 an analysis of studies conducted at the Bayer in-house ward  
 from 2000-2005

G.W. Wensing (DE)

09.00 - 09.30

Invited lecture

Title:

Use of surrogate endpoints versus clinical outcome  
 trials for registration trials

Speaker I 17

G. Calvo (ES)

09.30 - 10.00

Invited lecture

Title:

[Conference Theme Event](#)

Risk management plan: Bridging the gap between pre- and  
 post registration requirements

Speaker I 18

S. Strauss (NL)

10.00 - 10.30

Coffee

**Room A**

07.30 - 08.30

**Meet the expert sunrise session**

Title: Stem cell therapy: hope for the future?  
 Speaker I 19 T. Rabelink (NL)

**Room A**

08.30 - 08.45

**Cardiovascular***Chairpersons:*

D.J. Hausenloy (UK)

P. Smits (NL)

Abstract O 18

Chronobiological differences in the bioavailability of  
 nifedipine and isosorbide dinitrate

N.I. Bakracheva (BG)

08.45 - 09.00

Abstract O 19

Effect of oral antiplatelet drugs on major bleeding among  
 users of coumarin anticoagulants

T. Schalekamp (NL)

09.00 - 09.30	<p>Invited lecture</p> <p>Title: Pharmacological targets for protection of tissue against ischemia reperfusion injury</p> <p>Speaker I 20 D.J. Hausenloy (UK)</p>
09.30 - 10.00	<p>Invited lecture</p> <p>Title: Blood pressure lowering versus ancillary drug properties in cardiovascular prevention</p> <p>Speaker I 21 J.A. Staessen (BE)</p>
10.00 - 10.30	Coffee
<b>Room B</b>	<b>Meet the expert sunrise session</b>
07.30 - 08.30	<p>Title: Neuro-imaging in central nervous system drug development</p> <p>Speaker I 22 J. van Gerven (NL)</p>
<b>Room B</b>	<b>Neuropsychopharmacology</b>
	<i>Chairpersons:</i>
	E. Fuchs (DE)
	A. Loonen (NL)
08.30 - 08.45	<p>Abstract O 20 Concomitant use of serotonergic antidepressants as a determinant of lithium induced polyuria; a multicenter medical chart review study</p> <p>I. Wilting (NL)</p>
08.45 - 09.00	<p>Abstract O 21 Did the marketing of new antiepileptic drugs (AEDs) change the prescribing pattern of AEDs in Italy?</p> <p>G.T. Trifiro (IT)</p>
09.00 - 09.30	<p>Invited lecture</p> <p>Title: Translating symptoms via neurobiology</p> <p>Speaker I 23 G.S.E. Fernández (NL)</p>
09.30 - 10.00	<p>Invited lecture</p> <p>Title: Old and new pathophysiological mechanisms in the treatment of depression</p> <p>Speaker I 24 E. Fuchs (DE)</p>
10.00 - 10.30	Coffee
<b>Auditorium 1</b>	<b>Drug regulation</b>
	<i>Chairpersons:</i>
	A. Rane (SE)
	A.A.W. Kalis (NL)
10.30 - 10.45	<p>Abstract O 22 Assessing the cost-effectiveness of new medicines: the Scottish approach</p> <p>D.J. Webb (UK)</p>

10.45 - 11.00	Abstract O 23	Does the European Trial Directive lead to accelerated submission to approval time and harmonization in Europe? -a multicentre trial analysis in practice- H.J. Lambers Heerspink (NL)
11.00 - 11.30	Invited lecture Title: Speaker I 25	Off label use of drugs inevitable? Y. Hekster (NL)

**Room A****Pro-con***Chairpersons*

A. Vas (HU)

E.J. van Hoogdalem (NL)

**Conference Theme Event**

The patient populations extensively monitored in clinical drug development phase II and III cannot reflect the widely variable patient population exposed to a marketed drug. Clinical development should therefore be leaner and more focused on obtaining provisional marketing approval, followed by a post-marketing risk/benefit program enabling final approval.

10.30 - 10.45	Pro: Speaker I 26	G. Alvan (SW)
10.45 - 11.00	Con: Speaker I 27	A.F. Cohen (NL)
11.00 - 11.10	Plenary Discussion	
11.10 - 11.30	Late breaking Abstract O 24	Association between common polymorphisms in the slco1b1 gene (OATP1B1; OAPT-C) and the cholesterol-lowering effect of statins in a population-based survey W.S. Siegmund (DE)



**Room B****Neuropsychopharmacology***Chairpersons:*

G.S.E. Fernández (NL)

R. Kahn (NL)

10.30 - 10.45	Abstract O 25	A series of positron emission tomography (PET) studies on vinpocetine, a neuroprotective drug A. Vas (HU)
10.45 - 11.00	Abstract O 26	Observational study comparing the safety of antipsychotics in patients affected by dementia with behavioural and psychological symptoms of dementia (BPSD) A. Capuano (IT)

- 11.00 - 11.30 Invited lecture **Conference Theme Event**  
Title: Schizophrenia: disorder, spectrum or just genetic factor, any consequences for choice in treatment?  
Speaker I 28 R. Kahn (NL)
- Auditorium 1** **Plenary session**  
*Chairpersons:*  
N. Boada (ES)  
J.H. Beijnen (NL)  
**Conference Theme Event**
- 11.30-12.15 Title: New treatment strategies in the therapy on drugs of abuse  
Speaker I 29 W. van de Brink (NL)
- Poster area**  
12.15 - 13.00 Lunch + Poster viewing  
13.00 - 14.00 Guided Poster viewing
- Auditorium 1**  
13.00 - 14.00 General assembly of EACPT (open to all registrants)
- Auditorium 1**  
14.00 - 14.30 Plenary Poster discussion + Best Poster Award  
Moderator: K. Brösen (DK)
- Auditorium 1** **Clinical research in EU under the EU Directive in collaboration with IFAPP**  
*Chairpersons:*  
D. Criscuolo (IT)  
R. van Olden (NL)
- 14.30 - 15.00 Title: The assessment of clinical trials in the EU: time to change the role of competent authorities and research ethics committee?  
Speaker I 30 M. Kenter (NL)
- 15.00 - 15.20 Title: Future of investigator initiated trials in EU academia  
Speaker I 31 E. Singer (AT)
- 15.20 - 15.45 Title: Clinical research: globalization of industrial research  
Speaker I 32 H. Carmann (AT)
- 15.45 - 16.15 Coffee
- 16.15 - 16.35 Title: Experience of regulators with EU directive  
Speaker I 33 F. Pignatti (IT)
- 16.35 - 17.00 Title: Audits and inspections under the EU directive: latest findings.  
Speaker I 34 W.R. Verweij (NL)

- 17.00 - 18.45 IFAPP satellite symposium  
Pharmaceutical Medicine: the vision of IFAPP
- 18.45 - 19.30  Happy Hour
- Room A**
- Pharmacovigilance** **In collaboration with ISOP**  
*Chairpersons:*  
G. Velo (IT)  
A.C. van Grootheest (NL)
- 14.30 - 14.45 Abstract O 27 Drug interactions and adverse drug reactions in the elderly admitted to the emergency department of Ghent university hospital  
L.O. Outtier (BE)
- 14.45 - 15.15 Invited lecture  
Title: Will pharmacogenetics ever have a role in pharmacovigilance?  
Speaker I 35 M. Pirmohamed (UK)
- 15.15 - 15.45 Invited lecture  
Title: Safety in clinical trials  
Speaker I 36 L. Rago (ES)
- 15.45 - 16.15 Coffee
- 16.15 - 16.30 Abstract O 28 Relevance of polymorphic CYP2C9, CYP2C19 and CYP2D6 as a cause of serious adverse drug reactions  
P.A. Thürmann (DE)
- 16.30 - 17.00 Pharmacotherapeutic case  
Subject: Pharmacovigilance  
Title: From signals to drug prescription  
Speaker I 37 A.C. van Grootheest (NL)
- 17.00 - 18.45 **Satellite symposium GlaxoSmithKline**  
The (disease) burden of high cost medication, who is going to carry it?  
Vision from the pharmaceutical industry; vision from the ministry of health and a societal perspective: the willingness to pay for relieving the burden.
- 18.45 - 19.30  Happy Hour
- Room B**
- Oncology**  
*Chairpersons:*  
R. Mazzanti (IT)  
J.H.M. Schellens (NL)
- 14.30 - 14.45 Abstract O 29 Validation of discriminating serum protein profiles for colorectal cancer  
Y.M.N. Engwegen (NL)

14.45 - 15.00	Abstract O 30	5-Fluorouracil pharmacokinetic curve predicts disease-free survival in colorectal cancer adjuvant chemotherapy G. Pasqualetti (IT)
15.00 - 15.15	Abstract O 31	A clinical and pharmacological study with oral gemcitabine in patients with advanced solid tumors S.A. Veltkamp (NL)
15.15 - 15.45	Invited lecture Title: Speaker I 38	<b>Conference Theme Event</b> Long-term treatment results with trastuzumab in adjuvant breast cancer S.C. Linn (NL)
15.45 - 16.15	Coffee	
16.15 - 17.00	Pharmacotherapeutic case Subject: Title: Speaker I 39	Oncology Management of high-dose methotrexate therapy H. Helgason (IS)

17.00 - 18.45 **Satellite symposium Xceleron**  
Human Microdosing : Myths and Realities

18.45 - 19.30  Happy Hour

During the EACPT (European Association of Clinical Pharmacology and Therapeutics) congress Amsterdam RAI a TI Pharma/FIGON sponsored symposium will be organised. The aim of this symposium is to discuss the Toll-like receptor family and the possibilities this receptor family offers to develop new therapeutic strategies for various disease areas.

**Room C**  
14.00 - 17.00

**Symposium TI Pharma/FIGON: 'The Toll-like receptors and their clinical implications'**

*Chairpersons:*

A. Garritsen (Organon NL)  
D. de Zeeuw (chair FIGON NL)

Innovative research in the biomedical arena in the Netherlands:	
TI Pharma and FIGON	V.J. Nickolson (TI Pharma NL)
Toll-like receptors (TLR): introduction	M.G.Netea
Dendritic cell vaccination: use of TLR ligands	G.J. Adema
TLR in tumor immunology	C.J.M. Melief
TLRs in rheumatoid arthritis	T.R.D.J. Radstake

Closing remark: D. de Zeeuw (NL)

## Friday 31 August 2007

**Room C**

17.00 – 18.00 Council Meeting of EACPT (nominated delegates only)

**Auditorium 1**

07.30 - 08.30

**Meet the expert sunrise session in collaboration with ISPE**

Title: New tools in pharmacoepidemiology – value in the genotype, or just a genohype?  
Speaker I 40 O.H. Klungel (NL)

**Auditorium 1****Pharmacoepidemiology In collaboration with ISPE**

*Chairpersons:*

N. Moore (FR)  
H.G.M. Leufkens (NL)

08.30 – 08.45

Abstract O 32 QT-prolonging drugs: prescription pattern in general practice of Southern Italy during the years 2003 – 2005  
F.S. Salvo (IT)

08.45 – 09.00

Abstract O 33 Hormonal contraceptives and risk of aneurysmatic subarachnoid haemorrhage  
R. Risselada (NL)

09.00 – 09.30

Invited lecture  
Title: Bridging the world of randomized trials and pharmacoepidemiology  
Speaker I 41 A.W. Hoes (NL)

09.30 – 10.00

Invited lecture  
Title: Drug exposure as a key element of pharmacoepidemiology  
Speaker I 42 N. Moore (FR)

10:00 – 10.30

Coffee

**Room A**

07.30 - 08.30

**Meet the expert sunrise session**

Title: Altered pharmacology in the intensive care unit patient  
Speaker I 43 P. Geppetti (IT)

**Room A****Critical care Medicine**

*Chairpersons:*

P. Geppetti (IT)  
A. Girbes (NL)

08.30 – 08.45

Abstract O 34 Anticoagulation with argatroban in patients after cardiovascular surgery (ARGE03-study): dose-response relationship of coagulation parameters  
S. Harder (DE)

08.45 - 09.00 Abstract 0 35 Alkaline phosphatase improves renal function in patients with severe sepsis or septic shock  
S. Heemskerk (NL)

09.00 - 09.30 Invited lecture  
Title: Drug trials in sepsis  
Speaker I 44 A. Girbes (NL)

09.30 - 10.00 Invited lecture  
Title: Peri-operative pharmacotherapy  
Speaker I 45 B. Böttiger (DE)

10.00 - 10.30 Coffee

**Room B Meet the expert sunrise session Conference Theme Event**

07.30 - 08.30 Title: New avenues for development of drugs in children  
Speaker I 46 C. Knibbe (NL)

**Room B Metabolic disorders**

*Chairpersons:*  
J. Martinkova (CZ)  
G. Rongen (NL)

08.30 - 08.45 Abstract 0 36 Rosuvastatin inhibits ischemia-reperfusion injury in the forearm  
P. Meijer (NL)

08.45 - 09.00 Abstract 0 37 Correlates of LDL-cholesterol goal attainment in French patients receiving lipid lowering treatment in primary care  
E. van Ganse (FR)

09.00 - 09.30 Invited lecture  
Title: Thiazolidinedione derivatives in diabetes, an update  
Speaker I 47 H. Yki-Yärvinen (FI)

09.30 - 10.00 Invited lecture  
Title: Efficacy of lipid lowering pharmacotherapy in the elderly  
Speakers I 48 A.F.H. Stalenhoef (NL)

10.00 - 10.30 Coffee

**Auditorium 1 Pharmacoepidemiology In collaboration with ISPE**

*Chairpersons:*  
N. Moore (FR)  
A. de Boer (NL)

10.30 - 10.45 Abstract 0 38 Frequency and potential risk factors of hospital admissions related to medication (HARM) in the Netherlands  
A.J. Leendertse (NL)

10.45 - 11.00	Abstract O 39	Regional surveillance of emergency department visits for outpatient adverse drug events M.G. Gallo (IT)
11.00 - 11.30	Invited lecture Title: Speaker I 49	Cardiovascular research and pharmacoepidemiology T.M. McDonald (UK)

**Room A****Pro-con***Chairpersons:*

J. Cockcroft (UK)

D.D. Breimer (NL)

Title:

Clinical pharmacology and clinical pharmacy.  
Collaborating or competing disciplines?

10.30 - 10.45	Speaker collaborating I 50	J.H.M. Schellens (NL)
10.45 - 11.00	Speaker competing I 51	F. Sjöqvist (SE)

11.00 - 11.10	General discussion	
11.10 - 11.30	Late breaking presentation Abstract O 40	Dose individualization of indisulam to reduce the risk of severe myelosuppression A.S. Zandvliet (NL)

**Room B****Pediatric Pharmacotherapy***Chairpersons:*

A. Rane (SE)

K. Allegaert (BE)

10.30 - 10.45	Abstract O 41	Amikacin and tobramycin serum levels in paediatric cystic fibrosis patients on thrice-daily doses: a necessity for once-daily dosing regime implementation H. Tesfaye (CZ)
10.45 - 11.00	Abstract O 42	Rectal and oral omeprazole treatment of gastroesophageal reflux in infants; a pilot-study P. Bestebreurtje (NL)
11.00 - 11.30	Invited lecture Title: Speaker I 52	<a href="#">Conference Theme Event</a> ADHD: benefits and risks of drug treatment C. Gillberg (SE)

**Auditorium 1****Plenary lecture***Chairpersons:*

D.J. Webb (UK)

H.J. Guchelaar (NL)

11.30 - 12.15	Title:  Speaker I 53	Clinical significance of drug-induced QT-prolongation and related syndromes: an update A. Varro (HU)
---------------	----------------------------	---

**Poster area**

12.15 - 13.00 Lunch + Poster viewing

13.00 - 14.00 Guided Poster viewing

**Auditorium 1**

14.00 - 14.30 Plenary Poster discussion + Best Poster Award

Moderator: K. Dalhoff (DK)

**Auditorium 1**

**Pharmacoeconomics** **In collaboration with ISPOR**

*Chairpersons:*

P. Thürmann (DE)

A. de Boer (NL)

14.30 - 14.45

14.45 - 15.15

Invited lecture

Title: Pharmacoeconomics and reimbursement of new drugs

Speaker I 54 J.L. Severens (NL)

15.15 - 15.45

Invited lecture

Title: Application of economic evaluation methods to public health programmes

Speaker I 55 T. Walley (UK)

15.45 - 16.15

Coffee

16.15 - 17.00

Pharmacoeconomics case

Subject:

Title: Financial concerns and drug availability - a Western European perspective

Speaker I 56 P.A. Thürmann (DE)

Title: Financial concerns and drug availability - an Eastern European perspective

Speaker I 57 L. Ziganshine (RU)

**Room A**

**Digestive tract**

*Chairpersons:*

M. Neurath (DE)

P.A. van Meurs (NL)

14.30 - 14.45

Abstract O 43

Mesalazine and thiopurines: a dose-dependent interaction  
D.R. Wong (NL)

14.45 - 15.00

Abstract O 44

Gastrointestinal haemorrhage (GIH) produced by drug-drug interactions in the elderly: an approach by using the Spanish Database of Pharmacovigilance (FEDRA)  
N. Boada (ES)

15.00 - 15.15	Abstract 0 45	Acute ethanol co-ingestion reduces the risk of paracetamol-induced hepatotoxicity W.S. Waring (UK)
15.15 - 15.45	Invited lecture Title: Speaker I 58	Monoclonal antibodies in inflammatory bowel disease: from bench to bedside M. Neurath (DE)
15.45 - 16.15	Coffee	
16.15 - 16.30	Abstract 0 46	Your child is not my child: ambiguity of Child-Turcotte-Pugh classification in hepatic cirrhosis M.D.C.R. De Mey (DE)
16.30 - 17.00	Pharmacotherapeutic case Subject: Title: Speaker I 59	Digestive tract A case of drug-induced hepatitis M.I. Lucena (ES)
<b>Room B</b>	<b>Pulmonology</b> <i>Chairpersons:</i> R. Rodriguez-Roisin (ES) R.J.E. Grouls (NL)	
14.30 - 14.45	Abstract 0 47	Inhaled nitric oxide as a primary pulmonary hypertension treatment V. Shevchenko (UA)
14.45 - 15.15	Invited lecture Title: Speaker I 60	COPD as a systemic inflammatory disorder R. Rodriguez-Roisin (ES)
15.15 - 15.45	Invited lecture Title: Speaker I 61	<a href="#">Conference Theme Event</a> clinical pharmacology and pharmacogenetics of asthma and COPD D. Postma (NL)
15.45 - 16.15	Coffee	
16.15 - 16.30	Abstract 0 48	Novel therapy for allergy through gene silencing of CD40 using siRNA M.S Suzuki (CA)
16.30 - 17.00	Pharmacotherapeutic case Subject: Title: Speaker I 62	Pulmonology A case of cystic fibrosis present and future I. Fajac (FR)

**Auditorium 1** **Meet the expert sunrise session** **In collaboration with EURO-DURG**  
**Conference Theme Event**

07.30 - 08.30 Title: Strategies to improve rational prescribing  
 Speaker I 63 A. de Boer (NL)

**Auditorium 1** **Rational prescribing** **In collaboration with EURO-DURG**

*Chairpersons:*

J. Hallas (DK)  
 A.C. Egberts (NL)

08.30 - 08.45 Abstract O 49 Catch 22 : Doctor patient benzodiazepine?  
 A qualitative study exploring how GPs decide to prescribe a benzodiazepine to a patient for the first time

T.C. Christiaens (BE)

08.45 - 09.00 Abstract O 50 Differential association of genetic variation in renal organic anion transporters with the renal clearance of bumetanide, frusemide and torsemide

S.V. Vormfelde (DE)

09.00 - 09.30 Invited lecture

Title: Qualitative indicators of rational drug prescribing

Speaker I 64 F. Haaijer-Ruskamp (NL)

09.30 - 10.00 Invited lecture

Title: Quantitative indicators of rational drug prescribing

Speaker I 65 J. Hallas (DK)

10.00 - 10.30 Coffee

**Room A** **Meet the expert sunrise session**

**Conference Theme Event**

07.30 - 08.30 Title: Predictability of clinical pharmacokinetics by preclinical ADME

Speaker I 66 G.T. Tucker (UK)

**Room A** **Pharmacokinetics**

*Chairpersons:*

A.G. Lappin (UK)  
 E.J. van Hoogdalem (NL)

08.30 - 08.45 Abstract O 51 Effects of dose and opioid dependency on the pharmacokinetics of oral diacetylmorphine (heroin)

U. Halbsguth (CH)

08.45 - 09.00 Abstract 0 52 A PET study to assess the pharmacokinetics and sigma receptor occupancy in the brain of sa4503 at three dose levels in healthy male volunteers  
S. van Marle (NL)

09.00 - 09.30 Invited lecture  
Title: Less is more, faster: the human microdosing concept  
Speaker I 67 A.G. Lappin (UK)

09.30 - 10.00 Invited lecture  
Title: Microdosing: linearity of pharmacokinetics pushed to the extreme  
Speaker I 68 O. Bjerrum (DK)

10.00 - 10.30 Coffee

**Room B Meet the expert sunrise session**

07.30 - 08.30 Title: Pharmacotherapy and pharmacological studies in the elderly  
Speaker I 69 P.A.F. Jansen (NL)

**Room B Geriatric clinical pharmacology**

*Chairpersons:*  
K. Dalhoff (DK)  
P.A.F. Jansen (NL)

08.30 - 08.45 Abstract 0 53 Validity and reliability of the Simpson-Angus Scale (SAS) in recognition of medication induced parkinsonism in the elderly  
W. Knol (NL)

08.45 - 09.00 Abstract 0 54 Inappropriate drug combinations in geriatric psychiatry: comparative prevalence study in a university-affiliated psychiatric hospital  
H. Javelot (FR)

09.00 - 09.30 Invited lecture  
Title: Effects of pharmacotherapy for dementia, clinically relevant or only statistically significant?  
Speaker I 70 R.J. van Marum (NL)

09.30 - 10.00 Invited lecture  
Title: Pharmacokinetic and pharmacodynamic aspects of pharmacotherapy for cardiovascular diseases in the elderly  
Speaker I 71 S.H. Jackson (UK)

10.00 - 10.30 Coffee

**Room C**

**Antimicrobial use – European concerns**

*Chairpersons:*

I. Francetic (CR)

A. Sabo (YU)

08.30 – 08.45

Abstract O 55

Clinical pharmacokinetics of amphotericin B lipid formulations during artificial liver support

R.B. Bellmann (AU)

08.45 – 09.00

Abstract O 56

Pharmacokinetic and pharmacodynamic characteristics of oral valganciclovir in the treatment of children with CMV reactivation

M.L. Houben (NL)

09.00 – 09.30

Invited lecture

Title:

Antimicrobial use and the development of resistance

Speaker I 72

O. Cars (SE)

09.30 – 10.00

Invited lecture

Title:

Antibiotic use in Western European countries and quality indicators

Speaker I 73

R. Vander Stichele (BE)

10.00 – 10.30

Coffee

**Auditorium 1**

**Rational prescribing and Pharmacogenetics In collaboration with EURO-DURG**

*Chairpersons:*

I. Cascorbi (DE)

C. Kramers (NL)

10.30 - 10.45

Abstract O 57

Impact of CYP3A4, CYP3A5 and ABCB1 genotype and intestinal expression on the pharmacokinetics of budesonide

M.U. Ufer (DE)

10.45 - 11.00

Abstract O 58

Different effects of SLC01B1 polymorphism on the pharmacokinetics of atorvastatin and rosuvastatin

M.K. Pasanen (FI)

11.00 - 11.30

Invited lecture

Title:

[Conference Theme Event](#)

Pharmacogenetics-based new therapeutic concepts

Speaker I 74

I. Cascorbi (DE)

**Room A**

**Workshop on population analysis [Conference Theme Event](#)**

*Chairpersons:*

M. Karlsson (SE)

C. Neef (NL)

10.30 - 11.30	Case: Speaker I 75	Methods for modelling of population data M. Karlsson (SE) <a href="#">Conference Theme Event</a>
	Case: Speaker I 76	Population analysis in antiviral and oncological drug development A.D.R. Huitema (NL)

**Room B**

**Pro-con**

*Chairpersons:*

F. Sjöqvist (SE)

D. Burger (NL)

[Conference Theme Event](#)

Title: Therapeutic Drug Monitoring of aminoglycosides in neonates: a must !

10.30 - 10.45	Pro: Speaker I 77	Pro: K. Allegaert (BE)
10.45 - 11.00	Con: Speaker I 78	Con: D. Touw (NL)
11.00 - 11.10	Plenary Discussion	

11.10 - 11.30	Late breaking presentation Abstract O 59	Effect of allopurinol on serum uric acid levels and inflammatory markers in patients with recent ischaemic stroke C. Harrow (UK)
---------------	---	---

**Room C**

**Antimicrobial use – European concerns**

10.30 – 11.00	Invited lecture Title: Speaker I 79	Pharmacovigilance of antibiotic use in Eastern Europe J. Gulbinovic (SE)
11.00 – 11.30	Invited lecture Title: Speaker I 80	Interventions to optimise antibiotic prescribing in hospitals; the evidence from a Cochrane review. E.M. Brown (UK)

**Auditorium 1**

11.45 - 12.30 **Official Closing ceremony**

**Poster area**

12.30 - 13.30 Lunch

### Who should attend?

The programme will be of interest to anyone who has an interest in clinical pharmacology, drug regulation, drug research and development, teaching pharmacotherapy, pharmacoepidemiology, pharmacovigilance and application of pharmacotherapy in daily clinical practice. In addition, especially those who are in training for these specialties should attend the meeting. The organising committee will stimulate young investigators to present their scientific results.

### Best Abstract Awards

At the end of each poster discussion session a reward will be given to the authors of the best poster.

### Accreditation

International accreditation has been requested from FECS and ESMO. National accreditation has been requested at the Nederlandse Internisten Vereniging, Nederlandse Vereniging voor Heelkunde, Nederlandse vereniging voor Pathologie, Nederlandse Vereniging voor Radiotherapie en Oncologie, Nederlandse vereniging voor Ziekenhuisapothekers.

National accreditation has been granted by the:  
Nederlandsche Internisten Vereeniging 28 hours  
Nederlandse Vereniging voor Ziekenhuisapothekers 20 hours  
College voor Accreditering Huisartsen 8 hours  
Nederlandse Vereniging voor Reumatologie 22 hours  
Stichting Farmaceutische Geneeskunde 26 hours

### Internet Corner

Full Internet access will be available to meeting attendees at the Internet Corner. Users will be able to check and send e-mail and to surf the Internet. This service is provided due to a grant from Eisai Ltd.



### Registration

Participants may register on line at: [www.eacpt2007.nl](http://www.eacpt2007.nl)

Registration fees are in Euro (€) and include admission to all sessions, a programme and abstract book, coffee tea and lunches during the conference and a free public transport pass, valid for 72 hours, within the city of Amsterdam.

Registration fees	Regular	Students and residents in training
Early registration (before February 1, 2007)	€ 650	€ 350
Late (after February 1, 2007)	€ 750	€ 400
Conference dinner (Friday)	€ 90	€ 90

To qualify for early registration at the discounted rates, the application form must be completed and received by the registration bureau by February 1, 2007 ultimately. Full payment by credit card, check or by bank transfer must accompany your registration. Upon receipt of your registration, we will send you a confirmation of receipt. Registration at discounted rates after February 1, 2007 is not possible.

To qualify for student rates, students and residents in training must submit a letter from their supervisor on official letterhead, confirming their status.

Registration will be handled by:

Congress & Meeting Services Holland  
P.O. Box 18  
5298 ZG Liempde, The Netherlands  
P +31 (0)411 611 199  
F +31 (0)411 633 805  
[eacpt@congressservice.nl](mailto:eacpt@congressservice.nl)

### Payment

Bank transfers should be made payable to: Congress & Meeting Services Holland, P.O. Box 18, 5298 ZG Liempde, The Netherlands account number NL68 RABO 0198 2868 13 (SWIFT/BIC code: RABONL2U), with reference "EACPT2007", stating your name and full address. Please make sure your remittance is free of transfer charge.

Credit card box on the registration form should be checked. Number and expiration date should be filled out on the form as well.

### Cancellation

Reimbursement of the Registration fee minus € 50,- handling charges, will be made only if a written cancellation is received before July 1, 2007.

### **Social Programme**

All conference participants and accompanying persons are invited to the welcome reception on Tuesday, August 28, 2007 and the conference dinner on Friday, August 31st. Both social events will be excellent opportunities to meet your peers and friends in a relaxed atmosphere.

The conference dinner will be held in a special location in the Amsterdam area. Tickets (€ 90,- each) will be required and should be ordered in advance via the regular registration procedure.

### **Venue**

The conference will be hosted by Amsterdam RAI

Europaplein 22

NL 1078 GZ Amsterdam

P.O. Box 77777

NL 1070 MS Amsterdam

T 00 31 (0) 20 549 1212

F 00 31 (0) 20 646 4469

You will find a route description on the website [www.rai.nl](http://www.rai.nl)

### **Language**

The official conference language will be English. Simultaneous translation will not be provided.

### **Hotel Accommodation**

The official housing bureau, RAI Hotel & Travel Service, has reserved hotel rooms at special conference rates. Please visit our website: [www.eacpt2007.nl](http://www.eacpt2007.nl) for further details.

### **Weather**

Sunshine is common in August but the evenings may be cool. It is advisable to bring a sweater and a light raincoat.

### **Insurance**

Participants and partners are responsible for arranging their own full insurance cover for their travel to and from EACPT2007 and during their stay at EACPT2007, including any pre- and/or post-meeting events. The Organising Committee accepts no responsibility for accidents, illness, loss of life or loss of property incurred by participants or partners while in transit to and from the Symposium or during the Symposium and their stay in the Netherlands.

### **Flights to Amsterdam**

Online flight reservations to and from Amsterdam can be made through RAI Hotel & Travel Service. Our affiliate TQ3 is one of the largest travel agencies worldwide. They guarantee the lowest rates for flights around the globe, including low cost airlines such as Ryanair and EasyJet. All can easily be reserved online [www.eacpt2007.nl](http://www.eacpt2007.nl). You pay by credit card through a fully secured website. A confirmation will be sent directly by e-mail.

### **Airport transfers to your hotel**

Choose the easy way and book an airport transfer to your hotel online.

### **Tours & Excursions**

Visit our city of Amsterdam with the picturesque canal houses and graceful old buildings. Or experience the unique landscape of the Netherlands. Find and book the most popular excursions and tours through our online service. You can take advantage of the same low prices offered by touroperators in Amsterdam. Making your reservation in advance means you don't miss out on popular excursions, and you get the best price!

### **Car rental**

If you stay in the city centre of Amsterdam, you will probably use public transportation. But when you stay in the outskirts, or extend your stay elsewhere in the Netherlands, renting a car could be very useful. RAI Hotel & Travel Service offers attractive rates for car rental, which can easily be reserved online. We have compared different suppliers and guarantee the lowest available rates for Amsterdam and other destinations in the Netherlands. We also offer the lowest rates for rentals outside the Netherlands.

### **Visa Procedure**

The EACPT Conference is not responsible for any incorrect information on this issue. For a list of nationalities which require a visa to enter the Netherlands, and for information on fees, necessary papers, requirements and for further questions, please contact the Dutch Embassy or Consulate in your country.

Please allow at least two months for the visa application procedure. The conference organisation can provide you with a letter of invitation to participate in the conference. The organisation will only issue letters for the duration of the conference and for conference participants only (not for accompanying persons). No financial support can be given. If you need a letter of invitation, please contact the Conference Secretariat in time, preferably by e-mail: [eacpt@congresservice.nl](mailto:eacpt@congresservice.nl) or fax (+31 411 633805). Please state your full name, address and passport number, as well as the mailing address where the letter should be sent to.

**For information regarding registration and abstract submission:**

Congress & Meeting Services Holland  
P.O. Box 18  
5298 ZG Liempde, The Netherlands  
P: +31 (0)411 611 199  
F: +31 (0)411 633 805  
E: eacpt@congressservice.nl

**For information regarding Hotel reservations and Discount flights  
Amsterdam RAI Hotel & Travel Service**

P.O. Box 77777  
1070 MS Amsterdam  
Europaplein  
1078 GZ Amsterdam  
Telephone number +31 (0)20 549 1927  
Fax +31 (0)20 549 1946  
Email: hotelservice@rai.nl

**For information regarding the Scientific Programme**

Congress & Meeting Services Holland  
P.O. Box 18  
5298 ZG Liempde, The Netherlands  
P: +31 (0)411 611 199  
F: +31 (0)411 633 805  
E: eacpt@congressservice.nl

**Important dates**

**2006:**

September 1

Registration and abstract submission open

**2007:**


July 1

**28 August – 1 September**

Deadline for cancellation with reimbursement

**EACPT 2007 – Patient tailored pharmacotherapy**

Questions That Matter.



“Wordt mijn broertje snel weer beter?”

Bij Lilly houden we ons bezig met de belangrijkste vragen die er bestaan. Vragen over kwaliteit van leven, over genezing en het liefst zo spoedig mogelijk. Bij Lilly tulsteren we goed naar die vragen en zoeken we net zo lang tot we een antwoord gevonden hebben. Dat doen we door middel van baanbrekend onderzoek. Vandaar dat Lilly steeds vooroploopt bij het ontwikkelen van medicijnen die de beste of de eerste in hun klasse zijn. Zo hebben we in de loop der jaren een ongevenaarde medische expertise kunnen opbouwen. En hebben we antwoorden kunnen vinden op vragen die er echt toe doen. Zo kunnen we mensen helpen om een steeds langer, gezonder en actiever leven te leiden. Wilt u meer weten over onze Answers That Matter? Kijk dan op [www.lilly.nl](http://www.lilly.nl).

*Lilly*  
Answers That Matter.





**Diovan® 80, 160 en 320. Samenstelling:** Valsartan: filmomhulde tabletten met 80 mg, 160 mg en 320 mg. **Indicatie:** *Diovan 80, 160 en 320:* Behandeling van essentiële hypertensie. *Diovan 80 en 160:* Behandeling bij klinisch stabiele patiënten met symptomaatich hartfalen of asymptomatische linkerventrikel systolische disfunctie na een recent (12 uur - 10 dagen) myocardinfarct. Behandeling van symptomaatich hartfalen wanneer ACE-remmers niet gebruikt kunnen worden of als aanvullende therapie op een behandeling met ACE-remmers wanneer bèta-blokkers niet gebruikt kunnen worden. **Dosering:** *Hypertensie:* 80 mg éénmaaldaags. Wanneer de daling van de bloeddruk of de adequate bloeddrukcontrole onvoldoende is kan de dosis verhoogd worden tot 320 mg. Toevoeging van een diureticum zal de bloeddruk nog verder doen dalen. Diovan kan ook worden toegevend met andere antihypertensiva. *Recent myocardinfarct:* na een startdosering van 20 mg dient valsartan verhoogd te worden tot 40 mg, 80 mg en 160 mg tweemaaldaags gedurende de volgende paar weken. De maximale dosering is 160 mg tweemaaldaags. *Hartfalen:* startdosering is 40 mg tweemaaldaags. Verhoging tot 80 mg en 160 mg tweemaaldaags dient te gebeuren met intervallen van minimaal 2 weken. De maximale onderzochte dagdosering is 320 mg in verdeelde doses. **Contra-indicaties:** Overgevoeligheid voor één van de componenten, ernstig verminderde leverfunctie, biliaire cirrose en cholestase, ernstig verminderde nierfunctie (creatinineklaring <10 ml/min) en patiënten die gedialyseerd worden, zwangerschap en borstvoeding. **Waarschuwingen/voorzorgsmaatregelen:** Voorzichtigheid is geboden bij hyperkaliëmie en bij patiënten met natrium- en/of volumedepletie. Natrium- en/of volumedepletie dient gecorrigeerd te worden voor de start van de Diovan-behandeling. Unilaterale en bilaterale nierarterienose, recente niertransplantatie, aorta- en mitralisklepstenose, obstructieve hypertrofische cardiomyopathie, verminderde nierfunctie, verminderde leverfunctie en andere condities met stimulatie van het RAAS, zoals ACE-remmers. Diovan dient niet gebruikt te worden bij patiënten met primair hyperaldosteronisme. Bij patiënten met een mild tot matig verminderde leverfunctie zonder cholestase dient de dosering van 80 mg niet overschreden te worden. Tijdens de behandeling van hartfalen is het gebruik van Diovan in combinatie met ACE-remmers én bèta-blokkers niet aanbevolen. Tijdens de behandeling van patiënten met recent myocardinfarct en hartfalen is voorzichtigheid geboden en dient de nierfunctie regelmatig gecontroleerd te worden. Voorzichtigheid is geboden bij het besturen van voertuigen en het bedienen van machines. **Interacties:** Kaliumsupplementen, kaliumsparende diuretica, kaliumbevattende zoutsubstituten of andere geneesmiddelen die de kaliumspiegel kunnen verhogen. Andere antihypertensiva, NSAID's, ACE-remmers en lithium. **Bijwerkingen:** In gecontroleerde klinische studies met patiënten met hypertensie was de totale incidentie van bijwerkingen in de Diovan-groep vergelijkbaar met die in de placebo-groep. De incidentie van bijwerkingen bleek niet gerelateerd te zijn aan de dosis of behandelingsduur en toonde ook geen verband met geslacht, leeftijd of ras. Vaak: virale infecties, orthostatische duizeligheid\*, orthostatische hypotensie\*. Soms: infecties van de bovenste luchtwegen, faryngitis, sinusitis, hyperkaliëmie, depressie, slapeloosheid, syncope, conjunctivitis, vertigo, hartfalen\*, hypotensie, hoesten, epistaxis, diarree, buikpijn, ruggijn, spierkrampen, myalgie, artritis, vermoeidheid en asthenie. Zelden voorkomende, maar mogelijk ernstige bijwerkingen zijn overgevoeligheid inclusief serumziekte, vasculitis, angioneurotisch oedeem. Zeer zelden voorkomende, maar mogelijk ernstige bijwerkingen zijn gastro-enteritis, trombocytopenie, bloedingen, verminderde nierfunctie, acuut nierfalen en nierinsufficiëntie. Zie voor volledige vermelding van de bijwerkingen de Samenvatting van de Productkenmerken. **Alleverstatus:** U.R. **Verpakking en prijs:** Zie Z-index. **Vergoeding:** Volledige vergoeding. **Datering Samenvatting van de Productkenmerken:** Diovan 80 mg en 160 mg: september 2006, Diovan 320 mg: maart 2007.

Raadpleeg voor de volledige informatie de geregistreerde Samenvatting van de Productkenmerken. Te verkrijgen bij Novartis Pharma, Postbus 241, 6800 LZ Arnhem, 026-3782111, of via [www.novartis.nl](http://www.novartis.nl) \* is alleen waargenomen bij Diovan 80 en 160

**Co-Diovan® Samenstelling:** Valsartan en hydrochloorthiazide: filmomhulde tabletten: 80 mg/12,5 mg, 160 mg/12,5 mg en 160 mg/25 mg. **Indicatie:** Co-Diovan 80 mg/12,5 mg: Behandeling van essentiële hypertensie: indien aanvullende controle van bloeddruk naast valsartan- of hydrochloorthiazide monotherapie nodig is. Co-Diovan 160 mg/12,5 mg en 160 mg/25 mg: Behandeling van essentiële hypertensie indien aanvullende controle van bloeddruk naast valsartan monotherapie nodig is. **Dosering:** 1 Tablet éénmaaldaags. Individuele dosistitratie van de componenten is aanbevolen. De behandeling met Co-Diovan 160/12,5 mg dient gedurende 4-8 weken voortgezet te worden alvorens te starten met Co-Diovan 160/25. Zie voor volledige doseringbeschrijving de Samenvatting van de Productkenmerken. **Contra-indicaties:** Overgevoeligheid voor één van de componenten, ernstig verminderde leverfunctie, biliaire cirrose en cholestase, anurie, ernstige verminderde nierfunctie (creatinineklaring <30 ml/min) en patiënten die gedialyseerd worden, refractaire hypokaliëmie, hyponatriëmie, hypercalciëmie, symptomatische hyperurikemie, zwangerschap en borstvoeding. **Waarschuwingen/voorzorgsmaatregelen:** Gelijktijdig gebruik geneesmiddelen die elektrolytveranderingen kunnen veroorzaken. Patiënten die diuretica gebruiken, dienen periodiek gecontroleerd te worden op serumelektrolyten. Risico op hypotensie bij patiënten met natrium- en/of volumedepletie. Ernstig chronisch hartfalen en andere aandoeningen waarbij het RAAS is gestimuleerd. Patiënten die lijden aan nierinsufficiëntie (creatinineklaring  $\geq$  30 ml/min) dienen periodiek gecontroleerd te worden op serumkalium, creatinine- en urinezuurspiegels. Stenose van de renale arterie, recente niertransplantatie, primair hyperaldosteronisme, aorta- en mitralisklepstenose, obstructieve hypertrofische cardiomyopathie, verminderde leverfunctie, systemische lupus erythematoses. Etnische verschillen. Metabole stoornissen. Voorzichtigheid is geboden bij eerdere overgevoeligheid voor angiotensine-II-receptorblokkers. Voorzichtigheid is geboden bij het besturen van voertuigen en het bedienen van machines. **Interacties:** andere antihypertensiva, lithium, geneesmiddelen die de kaliumconcentratie verhogen of hyperkaliëmie indiceren. Zie de Samenvatting van Productkenmerken voor potentiële interacties die veroorzaakt kunnen worden door de thiazidecomponent van Co-Diovan. **Bijwerkingen:** Vaak: diarree; vermoeidheid; nasofaryngitis. Soms: abnormaal zicht; misselijkheid; dyspepsie; abdominale pijn; infecties van de bovenste luchtwegen of van de urinewegen; virale infecties; rhinitis; verhoogde serumspiegel van urinezuur; verhoogde bloedspiegels van bilirubine en creatinine; hypokaliëmie; hyponatriëmie; pijn aan ledematen; verstuikingen en verrekkingen; artritis; duizeligheid; hoesten; polyurie; pijn op de borst. Zelden: hypotensie. Zeer zelden: trombocytopenie; anemie; bloedingen; oedeem; alopecia; overgevoeligheid en allergische reacties; serumziekte; angio-oedeem; huidvasculitis; cardiale aritmieën. Zie voor volledige vermelding van de bijwerkingen van Co-Diovan en de potentiële bijwerkingen van Co-Diovan, die veroorzaakt kunnen worden door de afzonderlijke componenten, de Samenvatting van de Productkenmerken. **Alleverstatus:** U.R. **Verpakking en prijs:** zie Z-index. **Vergoeding:** Volledige vergoeding. **Datering Samenvatting van de Productkenmerken:** Co-Diovan 80/12,5: 22 juni 2004. Co-Diovan 160/12,5: 2 juli 2004. Co-Diovan 160/25: 29 september 2005. Raadpleeg voor de volledige informatie de geregistreerde Samenvatting van de Productkenmerken. Te verkrijgen bij Novartis Pharma, Postbus 241, 6800 LZ Arnhem, 026-3782111, of via [www.novartis.nl](http://www.novartis.nl)

Co-Diovan is uitsluitend geregistreerd voor behandeling van essentiële hypertensie. Zie voor volledige indicatiebeschrijving de Samenvatting van de Productkenmerken. Diovan is geïndiceerd voor: Behandeling van essentiële hypertensie. Behandeling bij klinisch stabiele patiënten met symptomaatich hartfalen of asymptomatische linkerventrikel systolische disfunctie na een recent myocardinfarct. Behandeling van symptomaatich hartfalen wanneer ACE-remmers niet gebruikt kunnen worden of als aanvullende therapie op een behandeling met ACE-remmers wanneer bèta-blokkers niet gebruikt kunnen worden. Zie voor volledige indicatiebeschrijving de Samenvatting van de Productkenmerken. Diovan 80 mg eenmaaldaags is de startdosering voor de behandeling van hypertensie. De behandeling met Co-Diovan 160/12,5 mg dient gedurende 4-8 weken voortgezet te worden alvorens te starten met Co-Diovan 160/25.

**Referenties:** 1. Lacourcière, Y. et al. Clin Ther 2005;27:1013-1021. Getoonde bloeddrukdaling bereikt na 8 weken. 2. Ruilope, L.M. et al. Clin Ther 2005;27:578-587. Getoonde bloeddrukdaling bereikt na 24 weken. 3. Diovan, Samenvatting van de Productkenmerken. 4. Co-Diovan, Samenvatting van de Productkenmerken. 5. IMS, Midas.



Novartis Pharma B.V., Postbus 241, 6800 LZ Arnhem

# First floor

